NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 82 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $101,721 | +18.6% | 122,556 | 0.0% | 0.00% | – |
| Q1 2023 | $85,789 | -31.2% | 122,556 | -50.0% | 0.00% | – |
| Q4 2022 | $124,762 | +60.0% | 245,112 | +100.0% | 0.00% | – |
| Q3 2022 | $78,000 | -38.1% | 122,556 | 0.0% | 0.00% | – |
| Q2 2022 | $126,000 | -88.6% | 122,556 | -79.1% | 0.00% | – |
| Q1 2022 | $1,101,000 | -60.6% | 585,627 | +1.0% | 0.00% | – |
| Q4 2021 | $2,795,000 | -36.7% | 579,976 | -5.0% | 0.00% | – |
| Q3 2021 | $4,413,000 | -61.3% | 610,424 | -50.6% | 0.00% | -100.0% |
| Q2 2021 | $11,400,000 | -41.4% | 1,235,098 | -21.8% | 0.00% | 0.0% |
| Q1 2021 | $19,438,000 | +17.1% | 1,579,068 | +34.1% | 0.00% | 0.0% |
| Q4 2020 | $16,601,000 | +148.6% | 1,177,350 | +111.5% | 0.00% | – |
| Q3 2020 | $6,679,000 | -20.7% | 556,577 | +9.7% | 0.00% | -100.0% |
| Q2 2020 | $8,419,000 | +5262.4% | 507,140 | +3587.5% | 0.00% | – |
| Q1 2020 | $157,000 | +4.7% | 13,753 | +13.2% | 0.00% | – |
| Q4 2019 | $150,000 | +328.6% | 12,153 | 0.0% | 0.00% | – |
| Q3 2019 | $35,000 | – | 12,153 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,047,300 | $5,048,000 | 1.07% |
| ACT CAPITAL MANAGEMENT, LLC | 212,500 | $1,024,000 | 0.74% |
| Redmile Group, LLC | 3,490,835 | $16,826,000 | 0.38% |
| Kynam Capital Management, LP | 147,000 | $709,000 | 0.38% |
| EcoR1 Capital, LLC | 860,619 | $4,148,000 | 0.13% |
| Baker Brothers Advisors | 3,821,740 | $18,421,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 130,899 | $631,000 | 0.08% |
| Sio Capital Management, LLC | 38,312 | $185,000 | 0.06% |
| Highland Private Wealth Management | 46,999 | $227,000 | 0.03% |
| XTX Topco Ltd | 10,018 | $48,000 | 0.03% |